生物标志物与心脏病。
Biomarkers and heart disease.
机构信息
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
出版信息
J Clin Sleep Med. 2011 Oct 15;7(5 Suppl):S9-11. doi: 10.5664/JCSM.1342.
Abstract
This review will focus on the evaluation of biomarkers and surrogate endpoints in chronic disease risk with a focus on cardiovascular disease. It provides an example of how identification of relevant biomarkers might be useful in sleep research and clinical care. Much of this review is derived from work performed by the Institute of Medicine (IOM) Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease (see footnote in the Acknowledgments). This discussion will review the committee charge, definitions of biomarkers and other endpoints, biomarker evaluation framework, case studies of representative biomarkers, recommendations, and conclusions.
摘要
这篇综述将重点关注慢性病风险的生物标志物和替代终点的评估，重点是心血管疾病。它提供了一个如何在睡眠研究和临床护理中识别相关生物标志物的例子。本综述的大部分内容源自医学研究所（IOM）慢性病生物标志物和替代终点资格认定委员会的工作（见致谢中的脚注）。本讨论将回顾委员会的任务、生物标志物和其他终点的定义、生物标志物评估框架、有代表性的生物标志物案例研究、建议和结论。
相似文献
1
Biomarkers and heart disease.生物标志物与心脏病。
J Clin Sleep Med. 2011 Oct 15;7(5 Suppl):S9-11. doi: 10.5664/JCSM.1342.
2
Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease.医学研究所报告的影响：慢性病生物标志物和替代终点的评估
Clin Pharmacol Ther. 2015 Jul;98(1):12-5. doi: 10.1002/cpt.129. Epub 2015 May 19.
3
Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relations.在饮食与慢性病关系的研究中，替代疾病标志物作为慢性病结局的替代指标。
Am J Clin Nutr. 2017 Nov;106(5):1175-1189. doi: 10.3945/ajcn.117.164046. Epub 2017 Oct 11.
4
Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.心血管疾病比较效果研究的未来方向：国家心肺血液研究所赞助的研讨会报告。
J Am Coll Cardiol. 2012 Aug 14;60(7):569-80. doi: 10.1016/j.jacc.2011.12.057. Epub 2012 Jul 11.
5
Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease.心血管疾病风险降低的替代终点和新兴替代终点。
Nutr Rev. 2008 Feb;66(2):76-81. doi: 10.1111/j.1753-4887.2007.00010.x.
6
7
Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short.维生素D与心血管疾病及糖尿病的预防：为何证据不足。
JAMA. 2011 Jun 22;305(24):2565-6. doi: 10.1001/jama.2011.881.
8
Conflict of Interest in Seminal Hepatitis C Virus and Cholesterol Management Guidelines.在丙型肝炎病毒和胆固醇管理指南中的利益冲突。
JAMA Intern Med. 2017 Mar 1;177(3):352-357. doi: 10.1001/jamainternmed.2016.8439.
9
Biomarker definitions and their applications.生物标志物的定义及其应用。
Exp Biol Med (Maywood). 2018 Feb;243(3):213-221. doi: 10.1177/1535370217750088.
10
The Institute of Medicine's report on medical error. Implications for pathology.
Arch Pathol Lab Med. 2000 Nov;124(11):1674-8. doi: 10.5858/2000-124-1674-TIOMSR.
引用本文的文献
1
No evidence of differential impact of sunflower and rapeseed oil on biomarkers of coronary artery disease or chronic kidney disease in healthy adults with overweight and obesity: result from a randomised control trial.没有证据表明葵花籽油和菜籽油对超重和肥胖的健康成年人的冠状动脉疾病或慢性肾病生物标志物有差异影响：一项随机对照试验的结果。
Eur J Nutr. 2022 Sep;61(6):3119-3133. doi: 10.1007/s00394-022-02810-5. Epub 2022 Apr 5.
2
Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?错误的蛋白质稳态：它能作为神经退行性疾病的生物标志物吗？
Mol Neurobiol. 2022 Jun;59(6):3382-3401. doi: 10.1007/s12035-022-02775-w. Epub 2022 Mar 19.
3
Milestones in Personalized Medicine: From the Ancient Time to Nowadays-the Provocation of COVID-19.个性化医疗的里程碑：从古代到现代——新冠疫情的激发
Front Genet. 2020 Nov 30;11:569175. doi: 10.3389/fgene.2020.569175. eCollection 2020.
4
Towards a Multivariate Biomarker-Based Diagnosis of Autism Spectrum Disorder: Review and Discussion of Recent Advancements.迈向基于多变量生物标志物的自闭症谱系障碍诊断：综述及最新进展讨论。
Semin Pediatr Neurol. 2020 Jul;34:100803. doi: 10.1016/j.spen.2020.100803. Epub 2020 Mar 5.
5
Suppression of HDAC by sodium acetate rectifies cardiac metabolic disturbance in streptozotocin-nicotinamide-induced diabetic rats.醋酸钠通过抑制组蛋白去乙酰化酶纠正链脲佐菌素-烟酰胺诱导的糖尿病大鼠心脏代谢紊乱。
Exp Biol Med (Maywood). 2020 Apr;245(7):667-676. doi: 10.1177/1535370220913847. Epub 2020 Mar 17.
6
Simultaneous detection and quantification of DNA and protein biomarkers in spectrum of cardiovascular diseases in a microfluidic microbead chip.在微流控微珠芯片中同时检测和定量心血管疾病谱中的 DNA 和蛋白质生物标志物。
Anal Bioanal Chem. 2019 Nov;411(29):7725-7735. doi: 10.1007/s00216-019-02199-x. Epub 2019 Nov 23.
7
Resting-State Functional Connectivity-Based Biomarkers and Functional MRI-Based Neurofeedback for Psychiatric Disorders: A Challenge for Developing Theranostic Biomarkers.基于静息态功能连接的生物标志物和功能磁共振神经反馈在精神障碍中的应用：治疗诊断生物标志物开发的挑战。
Int J Neuropsychopharmacol. 2017 Oct 1;20(10):769-781. doi: 10.1093/ijnp/pyx059.
8
Metabolic biomarkers for predicting cardiovascular disease.用于预测心血管疾病的代谢生物标志物。
Vasc Health Risk Manag. 2013;9:37-45. doi: 10.2147/VHRM.S30378. Epub 2013 Jan 29.
本文引用的文献
1
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.瑞舒伐他汀预防C反应蛋白升高的男性和女性发生血管事件。
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
2
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.初步报告：恩卡胺和氟卡胺在心肌梗死后心律失常抑制随机试验中对死亡率的影响
N Engl J Med. 1989 Aug 10;321(6):406-12. doi: 10.1056/NEJM198908103210629.
Zotero 插件